Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025

Rhea-AI Summary

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company specializing in rare genetic skin disease treatments, has scheduled its full year 2024 financial results announcement for March 31, 2025. The company will host a conference call with investors at 8:30 a.m. ET on the same day to discuss financial performance and provide a corporate update.

The presentation will include both a live webcast with slides and a dial-in option for participants. A replay of the webcast will be made available approximately 2 hours after the call concludes and will remain accessible for 90 days through the company's website.

News Market Reaction – PVLA

+1.31%

1 alert

+1.31% News Effect

On the day this news was published, PVLA gained 1.31%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

WAYNE, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its full year 2024 financial results on Monday, March 31, 2025.

Palvella management will host a conference call for investors at 8:30 a.m. ET on Monday, March 31, 2025, to discuss financial results and provide a corporate update.

To access the live webcast of the call with slides, please click here or visit the "Events & Presentations" section of Palvella’s website. To access the call by phone, please use this registration link, and you will be provided with dial in details. A replay of the webcast will be available approximately 2 hours after the conclusion of the call and archived for 90 days under the "Events & Presentations" section of the Company's website at www.palvellatx.com.

About Palvella Therapeutics

Founded and led by rare drug disease drug development veterans, Palvella Therapeutics (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being evaluated in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations and the Phase 2 TOIVA clinical trial in cutaneous venous malformations. For more information, please visit www.palvellatx.com or follow Palvella on LinkedIn or X (formerly known as Twitter).

QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency.

Contact Information

Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com

Media
Marcy Nanus
Managing Partner, Trilon Advisors, LLC
mnanus@trilonadvisors.com

FAQ

When will Palvella Therapeutics (PVLA) release its 2024 annual financial results?

Palvella Therapeutics will release its full year 2024 financial results on Monday, March 31, 2025.

What time is Palvella Therapeutics' (PVLA) 2024 earnings call scheduled for?

The earnings conference call is scheduled for 8:30 a.m. ET on Monday, March 31, 2025.

How long will Palvella Therapeutics' (PVLA) earnings call replay be available?

The webcast replay will be archived for 90 days on the company's website under the Events & Presentations section.

What is Palvella Therapeutics' (PVLA) primary business focus?

Palvella is a clinical-stage biopharmaceutical company developing therapies for serious, rare genetic skin diseases with no FDA-approved treatments.